GENFIT receives €26.5 million following a key milestone in Italy

GENFIT, a biopharmaceutical company listed on Nasdaq and Euronext, announced that it will receive a milestone payment of €26.5 million. This payment follows Ipsen's pricing and reimbursement approval for Iqirvo® in Italy for the treatment of primary biliary cholangitis. This decision is part of a licensing and collaboration agreement with Ipsen, validated in three major European markets.

Iqirvo® had already received these approvals in the UK and Germany. This payment will contribute to the development of drugs for acute on-chronic liver failure (ACLF) and other serious diseases. Milestone payments are excluded from the royalty-sharing agreement with HCRx.